Erythrodermic Psoriasis (EP) is a rare, severe and disabling form of psoriasis in children and adults. Clinical characteristics of this subtype of psoriasis include a diffuse erythema involving at least 75% of the body surface area, oedema, itch, scaling, hair loss, onychodystrophy, palmoplantar keratoderma and furthermore systemic findings. The triggers of erythrodermic psoriasis are an abrupt extraction of anti-psoriatic drugs such as methotrexate and topical steroids, systemic illness (e.g. HIV, infections), ultraviolet burns, drug reaction, abuse of alcohol, and emotional stress. Erythrodermic psoriasis may occur in association with life-threatening complications such as super infections and sepsis from skin pathogens such as Staphylococcus aureus and Streptococcus species, hypovolemic shock and acute kidney injury secondary to skin fluid loss, severe anemia, acute respiratory distress syndrome, hydroelectrolytic abnormalities and protein loss. Despite the plethora of treatment options for plaque psoriasis the management of erythrodermic psoriasis remains a challenge. Here we report a case of complete and rapid resolution of erythrodermic psoriasis with acitretin, demonstrating its efficacy for controlling the occurrence of erythrodermic flares, in a patient with moderate-to-severe plaque psoriasis effectively treated with secukinumab until then. Even today, in the era of biological agents, acitretin still remain a valuable treatment option for resistant and difficult to treat erythrodermic psoriasis.